Authors
Latest:
Ramucirumab: A Novel Antiangiogenic Agent for Gastric Cancer and Gastroesophageal Junction CancerAdvanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.
Latest:
Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder CancerCisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been the standard of care in muscle-invasive bladder cancer for almost 2 decades. However, the rates of NAC utilization remain low and many patients are ineligible to receive cisplatin due to diminished renal function or other factors. Additionally, there are no reliable biomarkers routinely used in clinical practice that identify patients most likely to benefit from NAC, and limited prospective comparisons of the NAC regimens.
Latest:
Results from a Phase III Trial Analyzing Obinutuzumab (GA101) in CLLValentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.
Latest:
Educating Patients With Melanoma on the Ramifications of Their DiagnosisValerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses educating patients with melanoma on their disease.
Latest:
Pembrolizumab Shows Durable Response in Advanced Unresectable Anal CancerVan K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.
Latest:
The Influence of the Gut Microbiome on Response to Anti-PD-1 Therapy in MelanomaVancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo's laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. Dr. Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator.
Latest:
Immunotherapy’s Potential in Neuro-OncologyA plenary session held November 15 at the Society of Neuro-Oncology’s (SNO) 2014 Annual Meeting in Miami Beach focused on immunotherapy’s promise as well as its challenges as a treatment for patients with brain cancer.
Latest:
PFS Improvement Seen in IMpower132 Trial for Patients With NSCLCVassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of thoracic medical oncology in the department of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, discusses the data that were presented at the World Conference on Lung Cancer earlier this year for the IMpower 132 trial comparing the combination of carboplatin/cisplatin plus atezolizumab (Tecentriq) to standard chemotherapy in patients with non–small cell lung cancer.
Latest:
Highlighting the Clinical Utility of Liquid Biopsies for Biomarker Detection in NSCLCDuring the 2019 AACR Annual Meeting, Vassiliki Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the NILE study and what they mean for the clinical utility of liquid biopsies for the detection of biomarkers in NSCLC.
Latest:
Clinical Validation and Utility of a Liquid Biopsy in NSCLCVeena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
Latest:
Ipilimumab in the Adjuvant Setting for MelanomaVernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
Latest:
Pazopanib for the Treatment of Soft Tissue SarcomaVicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
Latest:
Modest Response Rates in Endometrial CancersVicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib and pembrolizumab, in patients with endometrial cancers.
Latest:
Next Steps for CAR T Cells in B-Cell LymphomasVictor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.
Latest:
Outcomes in Progressive Large B-Cell Lymphomas Following CD19-Specific CAR T CellsVictor Chow, MD, senior hematology-oncology fellow, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses a retrospective study assessing outcomes of patients with large B-cell lymphomas and progressive disease following CD19-Specific CAR T-cell therapy during the 2018 ASH Annual Meeting.
Latest:
Combination Regimens on the Horizon in MelanomaVictoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses combination regimens on the horizon in melanoma.
Latest:
RAVD of Radiotherapy Using Induction Chemotherapy in LA-HNSCCVictoria M. Villaflor, MD, medical oncologist, associate professor, University of Chicago Medicine, discusses response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).
Latest:
Novel Proteasome Inhibitors for Multiple MyelomaThe recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.
Latest:
Optimizing Treatment in Patients With Resectable Pancreatic CancerVincent Picozzi, MD, discusses treatment for patients with pancreatic cancer who undergo surgery. Overall, the landscape lacks data on how to optimally sequence chemotherapy in patients with resectable disease.
Latest:
Identifying Unique Antigen Qualities in Long-Term Pancreatic Cancer SurvivorsVinod P. Balachandran, MD, Surgical Oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis to determine the unique antigen qualities of long-term survivors of pancreatic cancer during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Latest:
Expert Discusses Data for FLYER Trial in Patients With DLBCLViola Poeschel, MD, discusses the results for the phase III FLYER trial in which the standard 6 cycles of R-CHOP were compared to a reduced 4 cycles of R-CHOP in patients with diffuse large B-cell lymphoma
Latest:
Kaklamani's Insights on the EMERALD Trial and Elacestrant in Advanced Breast CancerIn this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, discusses the background, findings, and implications of the phase 3 EMERALD trial.
Latest:
An Expert's Overview of CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast CancerInhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor ER-positive HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.
Latest:
Acalabrutinib Shows High Response, Prolonged Survival in Ibrutinib-Intolerant R/R CLLBruton tyrosine kinase inhibitor acalabrutinib demonstrated a high rate of response, prolonged survival, and high tolerability in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib. Findings were presented at the 15th International Conference on Malignant Lymphoma.
Latest:
A Phase II Trial of Cetuximab and Docetaxel With Radiation for Head and Neck CancerThe use of low-dose radiotherapy may offer transient benefits; nonetheless the potential for palliative care exists.
Latest:
Addressing Adverse Events from Kinase Inhibitors in Thyroid CancerVivek Subbiah, MD, discusses the adverse events that come with the use of kinase inhibitors to treat patients with thyroid cancer.
Latest:
The Need for Better Surrogate Parameters for Overall Survival in Colorectal CancerVolker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.
Latest:
Sub-Centimeter Thyroid Nodule Size May Not Offer Good Prognostic Indicator for BiopsyThe rising overall risk of all sizes of malignant thyroid cancer has made clinicians question whether or not sub-centimeter thyroid nodules should also be biopsied.
Latest:
PD-L1 Strongly Correlates With Papillary Thyroid Cancer AggressivenessInvestigators at the Mount Sinai School of Medicine, Toronto, Canada, have been working on a potential correlation for aggressiveness and/or disease-free survival in thyroid cancer patients.
Latest:
RET Rearrangements in Non-Small Cell Lung CancerChromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer. These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468.
